Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any anti-diabetic medication and have been managing their condition through diet and ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment ... the end of this year. "If approved, the company is confident ...

Injectables for type 2 diabetes and weight loss could soon be ... If Orforglipron achieves approval by the U.S. Food and Drug Administration, Eli Lilly projected its confidence in launching ...

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

"As a convenient once-daily pill, orforglipron may provide a new option and, if approved ... Ozempic Type 2 diabetes injection drugs Additives in diet drinks, processed foods may raise type ...